Investigating inflammatory factors in acute kidney injury among ICU patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the role of inflammatory mediators in the development of acute kidney injury (AKI) in patients admitted to intensive care units. It focuses on patients with sepsis, those who have undergone major surgery, and non-inflamed individuals to identify novel inflammatory markers associated with AKI risk. By correlating these inflammatory levels with patient outcomes, the study seeks to enhance understanding of the mechanisms behind sepsis-induced AKI. The findings could lead to improved management strategies for at-risk patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients admitted to the intensive/post operative care unit

* with septic shock or
* post major surgery or
* after intoxication with a chemical compund

Exclusion Criteria:

* Pregnancy or
* Breast feeding or
* Chronic kidney disease or
* intoxication with nephrotoxic compund or
* lack of informed consent

Where it's running

• Akademiska sjukhuset, Centraloperation
  Uppsala, Uppsala County, Sweden Recruiting

Study contacts

• Study coordinator: Sara Bulow, MD
• Email: sara.bulow.anderberg@akademiska.se
• Phone: +46730247414

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Which antibiotic combo is safer for kidneys in serious hospital infections

  This trial tests whether vancomycin with piperacillin/tazobactam is gentler on the kidneys than other common broad-spectrum antibiotics for adults with serious infections in the hospital.

  Recruiting at 5 sites Phase 4 Bassett Healthcare · Worcester, Massachusetts and 6 other locations · NCT07556107

• Iron-chelator added to dialysis fluid in sepsis-related AKI on CRRT

  In adults with sepsis-associated acute kidney injury requiring dialysis, this study tests whether adding the iron-binding drug MEX-CD1 to dialysis fluid helps remove more iron compared with standard dialysis fluid.

  Recruiting Phase 1/2 Centre Hospitalier Universitaire de Nīmes · Nîmes, Gard and 1 other locations · NCT07236463

• AZD4144 for sepsis-associated acute kidney injury

  This will test whether IV AZD4144 given once daily can help adults with sepsis who recently developed acute kidney injury.

  Recruiting at 48 sites Phase 2 AstraZeneca · Phoenix, Arizona and 73 other locations · NCT07215702

• Using remote ischemic preconditioning to prevent kidney injury in septic patients

  This study is testing if a special technique that temporarily restricts blood flow in the arm can help prevent kidney injury in critically ill patients with sepsis.

  Recruiting Universität Münster · Münster · NCT05830669

• A large biobank for acute and emergency medicine

  This study is collecting health information and samples from patients with sudden illnesses in the Emergency Department to see if it can help improve treatments and predict how patients will do.

  Recruiting University Medical Center Groningen · Groningen · NCT04615065

• Using blood purification therapy for critically ill patients

  This study is trying to see which critically ill patients can benefit the most from a special blood purification treatment to help improve their recovery from serious conditions like kidney injury and sepsis.

  Recruiting Careggi Hospital · Florence · NCT04580680

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.